ACCENDRA director granted 31,191 restricted shares

Klemash Stephen W reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Klemash Stephen W reported acquisition or exercise transactions in this Form 4 filing.

ACCENDRA HEALTH INC/VA/ director Stephen W. Klemash received a grant of 31,191 shares of Common Stock as a restricted stock award. The grant was awarded at a price of $0.00 per share as part of equity compensation and increased his directly held shares to 90,242.

The restricted stock will vest on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. This is a compensation-related equity grant rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 31,191 shares

Grant/Award 1 txn

Insider Klemash Stephen W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	31,191	$0.00	$0.00

Holdings After Transaction: Common Stock — 90,242 shares (Direct)

Footnotes (1)

1. F1. Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

Key Figures

Restricted stock grant: 31,191 shares Grant price: $0.00 per share Shares held after grant: 90,242 shares +1 more

4 metrics

Restricted stock grant 31,191 shares Common Stock award to director on May 14, 2026

Grant price $0.00 per share Equity compensation award, not open-market purchase

Shares held after grant 90,242 shares Total direct Common Stock holdings following transaction

Vesting period Earlier of 1 year or next annual meeting Annual meeting must be at least 50 weeks after grant date

Key Terms

Restricted stock grant, Common Stock, annual meeting

3 terms

Restricted stock grant financial

"Restricted stock grant which vests the earlier of (i) one year"

A restricted stock grant is an award of company shares given to an employee or executive that cannot be sold or transferred until certain conditions are met, such as staying with the company for a set time or hitting performance goals. For investors, it signals how the company ties pay to future performance and can affect the number of shares outstanding and management’s incentives—think of it as a wrapped gift you only keep once you meet the requirements.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting financial

"the date of the next annual meeting that is at least 50 weeks"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACCENDRA HEALTH (ACH) director Stephen W. Klemash report in this Form 4?

Stephen W. Klemash reported receiving a restricted stock grant of 31,191 shares of ACCENDRA HEALTH Common Stock. The award was granted at $0.00 per share and is part of his equity compensation, rather than an open-market purchase of shares.

How many ACCENDRA HEALTH (ACH) shares does Stephen W. Klemash hold after this grant?

After the restricted stock grant, Stephen W. Klemash directly holds 90,242 shares of ACCENDRA HEALTH Common Stock. This total includes the newly granted 31,191 restricted shares, which are subject to vesting conditions described in the filing’s footnote.

What are the vesting terms of Stephen W. Klemash’s 31,191-share restricted stock grant at ACCENDRA HEALTH?

The 31,191-share restricted stock grant vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, the award remains subject to these time-based conditions.

Was Stephen W. Klemash’s ACCENDRA HEALTH Form 4 transaction an open-market buy or a compensation award?

The Form 4 transaction is a compensation-related restricted stock award, not an open-market share purchase. The grant of 31,191 Common Stock shares at $0.00 per share reflects an equity award classified as a grant or other acquisition under the Form 4 transaction code A.

Does this ACCENDRA HEALTH (ACH) Form 4 show any insider share sales by Stephen W. Klemash?

This Form 4 does not report any insider share sales by Stephen W. Klemash. It only shows a grant of 31,191 restricted shares, increasing his direct holdings to 90,242 shares, with no dispositions or open-market sales disclosed in this transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 09:13 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klemash Stephen W

(Last) (First) (Middle)

ACCENDRA HEALTH, INC.

4435 WATERFRONT DRIVE

(Street)

GLEN ALLEN VIRGINIA 23060

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACCENDRA HEALTH INC/VA/ [ ACH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/14/2026		A		31,191	A	$0	90,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

	Stephen W. Klemash by Rosemarie France POA	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)